261732-38-1

Basic information

• Product Name: tert-butyl 5-bromoindoline-1-carboxylate
• Synonyms: tert-butyl 5-bromoindoline-1-carboxylate;N-Boc-5-bromoindoline;1-BOC-5-bromoindoline;tert-Butyl 5-bromo-2,3-dihydroindole-1-carboxylate;5-Bromo-1-(tert-butyloxycarbonyl)-2,3-dihydro-1H-indole;1H-Indole-1-carboxylicacid,5-broMo-2,3-dihydro-,1,1-diMethylethylester;tert-butyl 5-broMo-2,3-dihydro-1H-indole-1-carboxylate;1,1-DiMethylethyl 5-broMo-2,3-dihydro-1H-indole-1-carboxylate
• CAS NO: 261732-38-1
• Molecular Formula: C₁₃H₁₆BrNO₂
• Molecular Weight: 298.19
• Mol File: 261732-38-1.mol
• Article Data: 32

Chemical Properties

• Melting Point: 126-128°C
• Boiling Point: 363℃
• Flash Point: 173℃
• Appearance: /
• Density: 1.400
• Storage Temp.: 2-8°C
• PKA: -0.02±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 5-bromoindoline-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 5-bromoindoline-1-carboxylate(261732-38-1)
• EPA Substance Registry System: tert-butyl 5-bromoindoline-1-carboxylate(261732-38-1)

Safety Data

• Hazard Codes: T,N
• Statements: 25-36/37/38-50/53
• Safety Statements: 26-45-60-61
• RIDADR: UN2811 - class 6.1 - PG 3 - EHS - Toxic solids, organic, n.o.s.,
• WGK Germany: 3
• Hazardous Substances Data: 261732-38-1(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

tert-Butyl 5-bromoindoline-1-carboxylate is a brominated indoline derivative and a product of biocatalyzed halogenation of nucleobase analogs. It is used in the synthetic preparation of biologic ally active compounds such as selective human β3 adrenergic receptor agonists.

Upstream product

• 22190-33-6 5-bromoindoline 
• 34619-03-9 tert-butyldicarbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 10075-50-0 5-bromo-1H-indole 

Downstream Products

• 879887-32-8 tert-butyl 5-formyl-2,3-dihydro-1H-indol-1-carboxylate 
• 143262-10-6 1-(tert-butoxycarbonyl)indoline 
• 1416980-05-6 (E)-tert-Butyl 5-(3-(3,5-dichloro-4-fluorophenyl)-4,4,4-trifluorobut-1-en-1-yl)indoline-1-carboxylate 
• 2300982-44-7 1-(5-{4-amino-7-ethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2,3-dihydro-1H-indol-1-yl)-2-[3-(trifluoromethoxy)phenyl]ethan-1-one 
• 874841-30-2 tert-butyl 5-cyanoindoline-1-carboxylate 
• 1593883-67-0 1-(phenylacetyl)-5-pyridin-3-yl-2,3-dihydro-1H-indole 
• 1610961-40-4 (3-methoxyphenyl)(5-(pyridin-3-yl)indolin-1-yl)methanone 
• 1593883-64-7 1-[(4-methoxyphenyl)carbonyl]-5-pyridin-3-yl-2,3-dihydro-1H-indole 

Relevant articles and documents

4-aminopyrrolopyrimidine derivative and preparation method and application thereof

The invention relates to a 4-aminopyrrolopyrimidine derivative and a preparation method and application thereof, and belongs to the field of medicines. The invention provides a compound shown as a formula I or pharmaceutically acceptable salt thereof. The

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model

We herein report the structural optimization and structure-activity relationship studies of 5-(2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors. Among all obtained RIPK1 inhibitors, 1-(5-{4-amino-7-ethyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-2,3-dihydro-1H-indol-1-yl)-2-[3-(trifluoromethoxy)phenyl]ethan-1-one (22b) is the most active one. This compound potently inhibited RIPK1 with a binding affinity (KD) of 0.004 μM and an enzymatic IC50 value of 0.011 μM and also showed good kinase selectivity. It could efficiently protect cells from necroptosis and attenuate the necrotic cell death of vascular endothelial cells induced by tumor cells both in vitro and in vivo. Importantly, compound 22b exhibited excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model. It also displayed favorable pharmacokinetic properties. Collectively, 22b could be a promising agent for preventing tumor metastasis.